Abstract
Chronic obstructive pulmonary disease (COPD) exacerbation is defined as an acute event characterized by a worsening of the patient’s respiratory symptoms that is beyond the normal day-to-day variations and leads to a change in medication. Since exacerbations are associated with deterioration of quality of life, accelerated rate of decline of lung function, increased mortality, and high socioeconomic costs, the prevention of exacerbations is one of the main targets of maintenance therapy for COPD. Exacerbations are largely a feature of moderate-to-severe COPD, with some COPD patients predisposed to frequent exacerbation phenotype, whose pulmonary functions show rapid deterioration. The most commonly used medications for COPD exacerbations are antibiotics, bronchodilators, and corticosteroids (ABC approach), while appropriate oxygen therapy and ventilator support are widely accepted as two major non-pharmacologic treatments. COPD exacerbations can often be prevented. Conforming to the management strategy for stable COPD patients is essential. Many types of pharmacologic and non-pharmacologic interventions such as long-acting inhaled bronchodilators and corticosteroids, phosphodiesterase inhibitor, and pulmonary rehabilitation program for posthospitalization periods are reported to be effective. Further understanding into the nature of exacerbations, invention of new effective interventions, and investigations to identify suitable combinations for interventions are required to develop more rational, preventive regimes for exacerbation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
The global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary diseases. Updated 2015. Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://www.goldcopd.org. Accessed 9 Dec 2015.
Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61:250–8.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–54.
Hurst JR, Vestbo J, Anzueto A, Locantore N, MĂ¼llerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
Langsetmo L, Platt RW, Ernst P, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med. 2008;177:396–401.
Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847–52.
Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786–96.
Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52.
Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63:951–5. doi:10.1136/thx.2007.092858.
Terada K, Muro S, Ohara T, Kudo M, Ogawa E, Hoshino Y, et al. Abnormal swallowing reflex and COPD exacerbations. Chest. 2010;137:326–32. doi:10.1378/chest.09-0482.
Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997;52:67–71.
Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55:114–20.
Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA. 2013;309:2353–61. doi:10.1001/jama.2013.5732.
Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261:274–82. doi:10.1148/radiol.11110173.
McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132:1748–55.
Devaraj A, Wells AU, Meister MG, Corte TJ, Wort SJ, Hansell DM. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology. 2010;254:609–16. doi:10.1148/radiol.09090548.
Wells JM, Washko GR, Han MK, Abbas N, Nath H, Mamary AJ, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367:913–21. doi:10.1056/NEJMoa1203830.
Li MH, Fan LC, Mao B, Yang JW, Choi AM, Cao WJ, et al. Short term exposure to ambient fine particulate matter (PM2.5) increases hospitalizations and mortality of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Chest. 2015 Jun 25. doi: 10.1378/chest.15-0513.
RodrĂguez-Roisin R. COPD exacerbations.5: management. Thorax. 2006;61:535–44.
Wells JM, Morrison JB, Bhatt SP, Nath H, Dransfield MT. Pulmonary artery enlargement is associated with cardiac injury during severe exacerbations of COPD. Chest. 2015. doi:10.1378/chest.15-1504.
Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax. 2012;67:1075–80. doi:10.1136/thoraxjnl-2012-201924.
Soler N, Esperatti M, Ewig S, Huerta A, Agustà C, Torres A. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J. 2012;40:1344–53. doi:10.1183/09031936.00150211.
El Moussaoui R, Roede BM, Speelman P, Bresser P, Prins JM, Bossuyt PM. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax. 2008;63:415–22. doi:10.1136/thx.2007.090613.
Barr RG, Rowe BH, Camargo Jr CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ. 2003;327(7416):643.
Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;1, CD001288. doi:10.1002/14651858.CD001288.
Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223–31. doi:10.1001/jama.2013.5023.
Walters JA, Wang W, Morley C, Soltani A, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;10, CD006897. doi:10.1002/14651858.CD006897.
Kiser TH, Allen RR, Valuck RJ, Moss M, Vandivier RW. Outcomes associated with corticosteroid dosage in critically ill patients with acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;189:1052–64. doi:10.1164/rccm.201401-0058OC.
Frat JP, Thille AW, Mercat A, Girault C, Ragot S, Perbet S, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–96. doi:10.1056/NEJMoa1503326.
Rittayamai N, Tscheikuna J, Praphruetkit N, Kijpinyochai S. Use of high-flow nasal cannula for acute dyspnea and hypoxemia in the emergency department. Respir Care. 2015;60(10):1377–82. doi:10.4187/respcare.03837.
Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G, Rauss A, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1997;336:817–22.
Esteban A, Anzueto A, Frutos F, AlĂa I, Brochard L, Stewart TE, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA. 2002;287:345–55.
Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005;26:234–41.
Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010;65:423–8. doi:10.1136/thx.2009.124164.
Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13–64. doi:10.1164/rccm.201309-1634ST.
Maddocks M, Kon SS, Singh SJ, Man WD. Rehabilitation following hospitalization in patients with COPD: can it reduce readmissions? Respirology. 2015;20:395–404. doi:10.1111/resp.12454.
Greening NJ, Williams JE, Hussain SF, Harvey-Dunstan TC, Bankart MJ, Chaplin EJ, et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ. 2014;349:g4315. doi:10.1136/bmj.g4315.
Echevarria C, Steer J, Heslop-Marshall K, Stenton SC, Hickey PM, Hughes R, et al. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. Thorax. 2016;71(2):133–40. doi:10.1136/thoraxjnl-2015-207775.
Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines preventing Pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;11, CD001390. doi:10.1002/14651858.CD001390.
Aaron SD. Management and prevention of exacerbations of COPD. BMJ. 2014;349:g5237. doi:10.1136/bmj.g5237.
Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199–209. doi:10.1016/S2213-2600(13)70052-3.
Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–94. doi:10.1056/NEJMoa1407154.
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–94. doi:10.1016/S0140-6736(09)61255-1.
Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–66. doi:10.1016/S0140-6736(14)62410-7.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper Jr JA, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–98. doi:10.1056/NEJMoa1104623.
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van't Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–8. doi:10.1016/S2213-2600(14)70019-0.
Zheng JP, Wen FQ, Bai CX, Wan HY, Kang J, Chen P, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–94. doi:10.1016/S2213-2600(13)70286-8.
Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim YI, et al. β-blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71:8–14. doi: 10.1136/thoraxjnl-2015-207251.
Fan VS, Gaziano JM, Lew R, Bourbeau J, Adams SG, Leatherman S, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012;156:673–83. doi:10.7326/0003-4819-156-10-201205150-00003.
Spencer S, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003;58:589–93.
O'Donnell DE, Parker CM. COPD exacerbations.3: pathophysiology. Thorax. 2006;61:354–61.
Tanabe N, Muro S, Hirai T, Oguma T, Terada K, Marumo S, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1653–9. doi:10.1164/rccm.201009-1535OC.
Freixa X, Portillo K, Paré C, Garcia-Aymerich J, Gomez FP, Benet M, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J. 2013;41:784–91. doi:10.1183/09031936.00222511.
Matsuoka S, Washko GR, Yamashiro T, Estepar RS, Diaz A, Silverman EK, et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med. 2010;181(3):218–25. doi:10.1164/rccm.200908-1189OC.
Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, Castro-Acosta A, Studnicka M, Kaiser B, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J. 2016;47:113–21. doi:10.1183/13993003.01391-2014.
Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67:957–63. doi:10.1136/thoraxjnl-2011-201518.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Mineshita, M. (2017). Exacerbation of COPD: Why Do Exacerbations of COPD Attract Attention? Are There Any Preventive Methods?. In: Nakamura, H., Aoshiba, K. (eds) Chronic Obstructive Pulmonary Disease. Respiratory Disease Series: Diagnostic Tools and Disease Managements. Springer, Singapore. https://doi.org/10.1007/978-981-10-0839-9_15
Download citation
DOI: https://doi.org/10.1007/978-981-10-0839-9_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-0838-2
Online ISBN: 978-981-10-0839-9
eBook Packages: MedicineMedicine (R0)